DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

Conditions

• Transthyretin Amyloidosis With Cardiomyopathy

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care

Key Dates

Start date

Jan 9, 2026

Status verified

Apr 2026

Primary completion

Oct 23, 2030

Completion

Oct 23, 2030

Study Design

Enrollment

2,000 participants (estimated)

Arms

• Arm: Patients with ATTR-CM
  Patients with ATTR-CM.

Primary Outcome Measure

New York Heart Association (NYHA) Class [ Time Frame: From time of ATTR-CM diagnosis up to 5 years ]

Central Contacts

• Clinical Trial Information Line
  1-877-ALNYLAM
  [email protected]
• Clinical Trial Information Line
  1-877-256-9526
  [email protected]

Locations (4)

Find similar trials in Naples, FL

Related Studies

• TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
  PHASE3 · Recruiting · Alnylam Pharmaceuticals · La Jolla, California